menu

Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keeping Pace in Hematologic Malignancies: 2023
Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

3 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Harry Paul Erba, MD, PhD
    Professor of Medicine
    Director, Leukemia Program
    Duke University
    Durham, NC

    Research: AbbVie, ALX Oncology, Amgen, Aptose, Ascentage, Daiichi Sankyo, Gilead, Glycomimetics, ImmunoGen, Jazz, MacroGenics, Novartis, PTC, Sumitomo Pharma
    Consulting Fees: AbbVie, Agios, Astellas, BMS/Celgene, Daiichi Sankyo, Glycomimetics, Incyte, Jazz, Kura Oncology, Novartis, Pfizer, Servier

    Faculty:
    Courtney DiNardo, MD, MSCE
    Associate Professor
    MD Anderson Cancer Center
    Houston, TX

    Research: AbbVie, BMS, Cleave, Foghorn, Loxo, Servier
    Consulting Fees: AbbVie, Astellas, BMS, Genentech, Gilead, Rigel, Schrödinger, Servier

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply diagnostic strategies to identify chemotherapy-eligible patients with newly diagnosed acute myeloid leukemia (AML) who would benefit from personalized induction/consolidation
    • Develop biomarker-driven treatment plans for induction and potential maintenance therapy in patients with newly diagnosed AML who are fit for intensive chemotherapy
    • Integrate evidence-based combination regimens promoting deep remission for patients with newly diagnosed AML who are ineligible for intensive chemotherapy
  • Target Audience

    This activity is designed to meet the educational needs of hematology oncologists, medical oncologists, oncology nurses, nurse practitioners, pathologists, radiation oncologists, pharmacists, physician assistants, and other HCPs treating patients with AML.

  • Accreditation and Credit Designation Statements


    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until DATE. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie Inc. and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Harry Paul Erba, MD, PhD
    Professor of Medicine
    Director, Leukemia Program
    Duke University
    Durham, NC

    Research: AbbVie, ALX Oncology, Amgen, Aptose, Ascentage, Daiichi Sankyo, Gilead, Glycomimetics, ImmunoGen, Jazz, MacroGenics, Novartis, PTC, Sumitomo Pharma
    Consulting Fees: AbbVie, Agios, Astellas, BMS/Celgene, Daiichi Sankyo, Glycomimetics, Incyte, Jazz, Kura Oncology, Novartis, Pfizer, Servier

    Faculty:
    Courtney DiNardo, MD, MSCE
    Associate Professor
    MD Anderson Cancer Center
    Houston, TX

    Research: AbbVie, BMS, Cleave, Foghorn, Loxo, Servier
    Consulting Fees: AbbVie, Astellas, BMS, Genentech, Gilead, Rigel, Schrödinger, Servier

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply diagnostic strategies to identify chemotherapy-eligible patients with newly diagnosed acute myeloid leukemia (AML) who would benefit from personalized induction/consolidation
    • Develop biomarker-driven treatment plans for induction and potential maintenance therapy in patients with newly diagnosed AML who are fit for intensive chemotherapy
    • Integrate evidence-based combination regimens promoting deep remission for patients with newly diagnosed AML who are ineligible for intensive chemotherapy
  • Target Audience

    This activity is designed to meet the educational needs of hematology oncologists, medical oncologists, oncology nurses, nurse practitioners, pathologists, radiation oncologists, pharmacists, physician assistants, and other HCPs treating patients with AML.

  • Accreditation and Credit Designation Statements


    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until DATE. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie Inc. and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 Feb 2024